Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 252

Similar articles for PubMed (Select 16732146)

1.

Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects.

Ray GT, Whitney CG, Fireman BH, Ciuryla V, Black SB.

Pediatr Infect Dis J. 2006 Jun;25(6):494-501.

PMID:
16732146
2.

Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.

Tyo KR, Rosen MM, Zeng W, Yap M, Pwee KH, Ang LW, Shepard DS.

Vaccine. 2011 Sep 2;29(38):6686-94. doi: 10.1016/j.vaccine.2011.06.091. Epub 2011 Jul 13.

PMID:
21745516
3.

Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.

Wisløff T, Abrahamsen TG, Bergsaker MA, Løvoll Ø, Møller P, Pedersen MK, Kristiansen IS.

Vaccine. 2006 Jul 17;24(29-30):5690-9. Epub 2006 May 5.

PMID:
16735083
4.

Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.

Melegaro A, Edmunds WJ.

Vaccine. 2004 Oct 22;22(31-32):4203-14.

PMID:
15474710
5.

The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine.

Isaacman DJ, Strutton DR, Kalpas EA, Horowicz-Mehler N, Stern LS, Casciano R, Ciuryla V.

Clin Ther. 2008 Feb;30(2):341-57. doi: 10.1016/j.clinthera.2008.02.003. Review.

PMID:
18343273
6.

Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects.

Lloyd A, Patel N, Scott DA, Runge C, Claes C, Rose M.

Eur J Health Econ. 2008 Feb;9(1):7-15. Epub 2007 Mar 2.

PMID:
17333089
7.

Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States.

Ray GT, Pelton SI, Klugman KP, Strutton DR, Moore MR.

Vaccine. 2009 Nov 5;27(47):6483-94. doi: 10.1016/j.vaccine.2009.08.045. Epub 2009 Aug 29.

PMID:
19720366
8.

Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: a new simulation model.

De Wals P, Black S, Borrow R, Pearce D.

Clin Ther. 2009 Oct;31(10):2152-69. doi: 10.1016/j.clinthera.2009.10.014.

PMID:
19922887
9.

Economic evaluation of pneumococcal conjugate vaccination in The Gambia.

Kim SY, Lee G, Goldie SJ.

BMC Infect Dis. 2010 Sep 3;10:260. doi: 10.1186/1471-2334-10-260.

10.

Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.

Ortega-Sanchez IR, Meltzer MI, Shepard C, Zell E, Messonnier ML, Bilukha O, Zhang X, Stephens DS, Messonnier NE; Active Bacterial Core Surveillance Team.

Clin Infect Dis. 2008 Jan 1;46(1):1-13. doi: 10.1086/524041.

11.

Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines.

Rozenbaum MH, Sanders EA, van Hoek AJ, Jansen AG, van der Ende A, van den Dobbelsteen G, Rodenburg GD, Hak E, Postma MJ.

BMJ. 2010 Jun 2;340:c2509. doi: 10.1136/bmj.c2509.

12.
13.

The cost-effectiveness of pneumococcal conjugate vaccination in Australia.

Butler JR, McIntyre P, MacIntyre CR, Gilmour R, Howarth AL, Sander B.

Vaccine. 2004 Mar 12;22(9-10):1138-49.

PMID:
15003641
14.

Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine.

Lacapa R, Bliss SJ, Larzelere-Hinton F, Eagle KJ, McGinty DJ, Parkinson AJ, Santosham M, Craig MJ, O'Brien KL.

Clin Infect Dis. 2008 Aug 15;47(4):476-84. doi: 10.1086/590001.

15.

A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain.

Asensi F, De Jose M, Lorente M, Moraga F, Ciuryla V, Arikian S, Casciano R, Vento M.

Value Health. 2004 Jan-Feb;7(1):36-51.

PMID:
14720129
16.

Pharmacoeconomic assessment of implementing a universal PCV-13 vaccination programme in the Valencian public health system (Spain).

Díez-Domingo J, Ridao-López M, Gutiérrez-Gimeno MV, Puig-Barberá J, Lluch-Rodrigo JA, Pastor-Villalba E.

Vaccine. 2011 Dec 6;29(52):9640-8. doi: 10.1016/j.vaccine.2011.10.038. Epub 2011 Oct 24.

PMID:
22027484
17.
18.

Economic evaluation of a universal childhood pneumococcal conjugate vaccination strategy in Ireland.

Tilson L, Usher C, Butler K, Fitzsimons J, O'Hare F, Cotter S, O'Flanagan D, Johnson H, Barry M.

Value Health. 2008 Sep-Oct;11(5):898-903. doi: 10.1111/j.1524-4733.2008.00341.x. Epub 2008 May 16.

PMID:
18489504
19.
20.

Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction--eight states, 1998-2005.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2008 Feb 15;57(6):144-8.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk